Glycolytic and fatty acid oxidation genes affect the treatment and prognosis of liver cancer

Figure 7 Prediction of the efficacy of immune checkpoint blockade therapy and chemotherapy drugs in different metabolic subgroups. A: Distribution of Tumour Immune Dysfunction and Exclusion scores in glycolytic subtype of liver hepatocellular carcinoma vs fatty acid oxidation subtype of liver hepatocellular carcinoma; B: Box plot shows samples with response if immune checkpoint blockade therapy; C: Half-maximum inhibitory concentration of clinical anti-cancer drugs forecasted by Genomics of Drug Sensitivity in Cancer.